Vertex Pharmaceuticals Incorporated (LON:0QZU)
London flag London · Delayed Price · Currency is GBP · Price in USD
454.69
-5.81 (-1.26%)
Dec 5, 2025, 5:08 PM BST

Revenue

Fiscal year is January - December.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 2013 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Trikafta / Kaftrio Revenue
10.46B10.24B
Log In
Log In
Log In
Upgrade
Symdeko / Symkevi Revenue
--
Log In
Log In
Log In
Upgrade
Orkambi Revenue
--
Log In
Log In
Log In
Upgrade
Kalydeco Revenue
--
Log In
Log In
Log In
Upgrade
Casgevy Revenue
69.50M10.00M
Log In
Log In
Log In
Upgrade
Other Product Revenue
773.90M781.50M
Log In
Log In
Log In
Upgrade
Net Product Revenue
11.69B11.02B
Log In
Log In
Log In
Upgrade
Other Collaborative and Royalty Revenue
--
Log In
Log In
Log In
Upgrade
Revenue (Other)
-11.30B-11.03B
Log In
Log In
Log In
Upgrade
Revenue (Total)
11.69B11.02B
Log In
Log In
Log In
Upgrade
Other Collaborative and Royalty Revenue
--
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 2013 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Other Collaborative and Royalty Revenue
--
Log In
Log In
Log In
Upgrade
Other Collaborative and Royalty Revenue
--
Log In
Log In
Log In
Upgrade
United States Product Revenue
7.29B6.68B
Log In
Log In
Log In
Upgrade
Outside of United States Product Revenue
4.40B4.34B
Log In
Log In
Log In
Upgrade
Revenue (Total)
11.69B11.02B
Log In
Log In
Log In
Upgrade